IL1B and neoplasm: However, despite reduced systemic immunity, MLX01 treatment delayed the growth of primary tumours; this may be because IL1β has been shown to drive both anti-tumour and pro-tumour effects via stimulating infiltration of innate anti-tumour immune cells and creating an immuno-suppressive microenvironment by increasing the infiltration of myeloid-derived suppressor cells (MDSCs), [10,32,33].